As a sponsor of Alliance for Regenerative Medicine's #MeetingontheMesa, we are dedicated to advancing the future of cell and gene therapy. With emerging manufacturers facing complex hurdles in government pricing programs and compliance, our expertise across our Riparian LLC and Two Labs companies offers the strategic insights you need to navigate these challenges successfully. From Medicaid pricing complexities to the strategic use of Value-Based Agreements (VBAs), we bring unparalleled insights to help you ensure patient access and maintain compliance in a rapidly evolving landscape. Our integrated solutions are designed to empower your journey from strategy to implementation. Explore our latest insights from Jennifer Lospinoso, Managing Director & Consulting Lead at Riparian LLC, on overcoming pricing and compliance challenges in CGTs. #CellandGeneTherapy #MeetingontheMesa #GovernmentPricing
Emerging manufacturers face critical hurdles with government pricing programs, especially when it comes to cell and gene therapies. From enrolling in the Medicaid Drug Rebate Program to navigating the complexities of best-price reporting, ensuring compliance is no small feat. With Value-Based Agreements (VBAs) becoming a vital strategy, how can you effectively manage pricing while ensuring patient access? Explore Jennifer Lospinoso, Managing Director & Consulting Lead at Riparian LLC, latest insights on overcoming these challenges, staying compliant, and ensuring your CGTs reach those who need it most. Read her full insights here: https://bit.ly/47lCfK2